State Public Policy Initiatives
FORCE is engaged in a variety of state legislative initiatives—affordable access to genetic testing, high-risk “supplemental” cancer screenings, fertility treatments and cancer therapies, banning genetic discrimination, etc.—representing the unique needs of individuals with or at risk of hereditary cancer.
Note: The 2025 state legislative sessions are just beginning. Policy efforts will be added as they emerge.
Genetic testing
HB2292 will require private/commercial health insurers to cover genetic counseling and multigene panel testing with no patient cost-sharing for individuals with a family history of cancer.
Genetic counselor licensure
HB2028 will facilitate state licensure of genetic counselors by the American Board of Genetic Counseling (ABGC).
Colon cancer screening
HB5174 will require that individuals and group health insurers cover physician-recommended screening and diagnostic colonoscopies with no patient cost-sharing.
Fertility services
HB94 will facilitate insurance coverage of fertility preservation for individuals with diagnosed cancer, sickle cell disease, or lupus.
Protections against genetic discrimination
SB0250 will prohibit life, long-term care and disability insurers from using genetic information when considering benefits, fees or coverage determinations.
Breast cancer research
HB1299 will require the Indiana department of health to establish a program to provide research grants to cancer centers in the state.
High-risk breast screenings and diagnostic tests
HB1061 will require that health insurers cover medically appropriate breast screenings (breast mammograms, MRIs and ultrasounds) for women at increased risk of breast cancer and diagnostic services with no patient cost-sharing.
Fertility services
Legislation will facilitate Medicaid and private/commercial insurance coverage of the diagnosis and treatment of infertility, including medically appropriate fertility preservation and in-vitro fertilization (IVF).
Fertility services
SB2031 will facilitate insurance coverage of fertility preservation for individuals who may become infertile due to surgery or medical treatment.
Genetic counseling and testing
HB1080 would require most health insurers to cover genetic counseling and multigene panel genetic testing with no patient cost-sharing.
Genetic counseling and BRCA genetic testing
SB406 will require health insurers to cover genetic counseling and BRCA genetic testing with no patient cost-sharing.
Protections against genetic discrimination
LB338 will prohibit life, long-term care and disability insurers from using genetic information when considering benefits, fees or coverage determinations.
High-risk breast screenings and diagnostic tests
Bill will expand and improve current statutes, requiring private/commercial health insurers to cover breast screenings (breast MRIs, diagnostic mammograms and ultrasounds) for individuals with a family history of cancer or additional factors that may increase their cancer risk with no cost-sharing for the patient.
Fertility services
HB95 will require insurance coverage of fertility preservation services for individuals whose disease or disease treatment may lead to infertility.
Fertility Services
S2619 will require coverage of IVF by individual insurance plans and remove the three-cycle limit on group health plan coverage of IVF.
Genetic testing
S520 will ensure ovarian cancer survivors have insurance coverage for medically necessary coverage of genetic and biomarker testing.
Protections against genetic discrimination
Legislation will prohibit life, long-term care and disability insurers from using genetic information when considering benefits, fees or coverage determinations.
Fertility services
HB1282 will facilitate insurance coverage of the diagnosis and treatment of infertility, including medically appropriate fertility preservation and in-vitro fertilization (IVF).
Fertility services
HB1284 will facilitate insurance coverage of fertility preservation for individuals who may become infertile due to surgery or medical treatment.
High-risk breast screenings and diagnostic tests
HB1283 will require most health insurers to cover guideline-recommended breast screenings (breast MRIs, diagnostic mammograms, and breast ultrasounds) and diagnostic imaging with no patient cost-sharing.
Genetic testing and associated cancer screenings
SB109 will require health insurers to cover genetic testing and evidence-based cancer screenings for individuals at increased cancer risk with no patient cost-sharing.
High-risk breast screenings and diagnostic tests
HB1389 will require that health insurers cover guideline-recommended breast screenings (mammograms, MRIs and ultrasounds) for women at increased risk of breast cancer and diagnostic services with no patient cost-sharing.
High-risk prostate cancer screening
HB281 will require most health insurers to cover prostate cancer screening for individuals at increased risk.
High-risk breast screenings and diagnostic tests
H3202 will require all state health insurers to cover guideline-recommended supplemental breast screenings (breast MRIs and breast ultrasounds) and diagnostic exams with no patient cost-sharing.
Protections against genetic discrimination
H2357 will prohibit life, long-term care and disability insurers from using genetic information when considering benefits, fees or coverage determinations.
Breast screenings and diagnostic tests
HB1070 will require most group health insurers to cover guideline-recommended supplemental breast screenings (breast MRIs and breast ultrasounds) and diagnostic exams with no patient cost-sharing.
Fertility services
HB1609 will facilitate private/commercial insurance coverage of the diagnosis and treatment of infertility, including fertility preservation and in-vitro fertilization (IVF).
High-risk breast screenings and diagnostic tests
HB1828 will require private/commercial health insurers to cover supplemental breast screenings (breast MRIs and breast ultrasounds) and diagnostic exams with no patient cost-sharing for individuals in accordance with National Comprehensive Cancer Network (NCCN) guidelines.